[PDF][PDF] The CD38/NAD/SIRTUIN1/EZH2 axis mitigates cytotoxic CD8 T cell function and identifies patients with SLE prone to infections

E Katsuyama, A Suarez-Fueyo, SJ Bradley, M Mizui… - Cell reports, 2020 - cell.com
E Katsuyama, A Suarez-Fueyo, SJ Bradley, M Mizui, AV Marin, L Mulki, S Krishfield…
Cell reports, 2020cell.com
Patients with systemic lupus erythematosus (SLE) suffer frequent infections that account for
significant morbidity and mortality. T cell cytotoxic responses are decreased in patients with
SLE, yet the responsible molecular events are largely unknown. We find an expanded
CD8CD38 high T cell subset in a subgroup of patients with increased rates of infections.
CD8CD38 high T cells from healthy subjects and patients with SLE display decreased
cytotoxic capacity, degranulation, and expression of granzymes A and B and perforin. The …
Summary
Patients with systemic lupus erythematosus (SLE) suffer frequent infections that account for significant morbidity and mortality. T cell cytotoxic responses are decreased in patients with SLE, yet the responsible molecular events are largely unknown. We find an expanded CD8CD38high T cell subset in a subgroup of patients with increased rates of infections. CD8CD38high T cells from healthy subjects and patients with SLE display decreased cytotoxic capacity, degranulation, and expression of granzymes A and B and perforin. The key cytotoxicity-related transcription factors T-bet, RUNX3, and EOMES are decreased in CD8CD38high T cells. CD38 leads to increased acetylated EZH2 through inhibition of the deacetylase Sirtuin1. Acetylated EZH2 represses RUNX3 expression, whereas inhibition of EZH2 restores CD8 T cell cytotoxic responses. We propose that high levels of CD38 lead to decreased CD8 T cell-mediated cytotoxicity and increased propensity to infections in patients with SLE, a process that can be reversed pharmacologically.
cell.com